Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence

Choosing optimal anti-seizure medication (ASM) is very important in pediatric patients with epilepsy who attend school, especially children with an intellectual disability (ID). Levetiracetam (LEV) has proven to be an effective, safe, generally well-tolerated, broad-spectrum ASM in children. In the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ja Un Moon, Ji Yoon Han
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	levetiracetam anti-seizure medications intellectual disability epilepsy children efficacy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/ac13ae2b7de64dbb9dca02988a2316ca
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ac13ae2b7de64dbb9dca02988a2316ca
record_format	dspace
spelling	oai:doaj.org-article:ac13ae2b7de64dbb9dca02988a2316ca2021-11-25T16:57:40ZComparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence10.3390/brainsci111114522076-3425https://doaj.org/article/ac13ae2b7de64dbb9dca02988a2316ca2021-10-01T00:00:00Zhttps://www.mdpi.com/2076-3425/11/11/1452https://doaj.org/toc/2076-3425Choosing optimal anti-seizure medication (ASM) is very important in pediatric patients with epilepsy who attend school, especially children with an intellectual disability (ID). Levetiracetam (LEV) has proven to be an effective, safe, generally well-tolerated, broad-spectrum ASM in children. In the context of increasing use of LEV in school-aged children with epilepsy and ID, we evaluate relevant clinical data, including efficacy, safety, and tolerability in children with epilepsy and an intellectual disability (ID) or normal intelligence (NI). We performed a retrospective chart review of children and included 298 pediatric patients with epilepsy who were treated with LEV with NI (147) and ID (151). After 6 months, 96% of NI and 83% of ID subjects had a seizure reduction rate greater than 50% (<i>p =</i> 0.031). The tolerability of LEV was generally good, with 75% retention rates at 2 years in both groups and only minor side effects (under 15%). The retention rates of patients with NI and ID were 76% and 74%, respectively (<i>p =</i> 0.597). Thus, LEV showed considerable efficacy with minimal side effects and high retention rates and is an easily maintained and safe treatment option for pediatric epilepsy with ID. However, better-designed research studies are needed to clearly elucidate the efficacy and safety of LEV in children with epilepsy and ID.Ja Un MoonJi Yoon HanMDPI AGarticlelevetiracetamanti-seizure medicationsintellectual disabilityepilepsychildrenefficacyNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain Sciences, Vol 11, Iss 1452, p 1452 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	levetiracetam anti-seizure medications intellectual disability epilepsy children efficacy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	levetiracetam anti-seizure medications intellectual disability epilepsy children efficacy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Ja Un Moon Ji Yoon Han Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence
description	Choosing optimal anti-seizure medication (ASM) is very important in pediatric patients with epilepsy who attend school, especially children with an intellectual disability (ID). Levetiracetam (LEV) has proven to be an effective, safe, generally well-tolerated, broad-spectrum ASM in children. In the context of increasing use of LEV in school-aged children with epilepsy and ID, we evaluate relevant clinical data, including efficacy, safety, and tolerability in children with epilepsy and an intellectual disability (ID) or normal intelligence (NI). We performed a retrospective chart review of children and included 298 pediatric patients with epilepsy who were treated with LEV with NI (147) and ID (151). After 6 months, 96% of NI and 83% of ID subjects had a seizure reduction rate greater than 50% (<i>p =</i> 0.031). The tolerability of LEV was generally good, with 75% retention rates at 2 years in both groups and only minor side effects (under 15%). The retention rates of patients with NI and ID were 76% and 74%, respectively (<i>p =</i> 0.597). Thus, LEV showed considerable efficacy with minimal side effects and high retention rates and is an easily maintained and safe treatment option for pediatric epilepsy with ID. However, better-designed research studies are needed to clearly elucidate the efficacy and safety of LEV in children with epilepsy and ID.
format	article
author	Ja Un Moon Ji Yoon Han
author_facet	Ja Un Moon Ji Yoon Han
author_sort	Ja Un Moon
title	Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence
title_short	Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence
title_full	Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence
title_fullStr	Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence
title_full_unstemmed	Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence
title_sort	comparative efficacy of levetiracetam for epilepsy in school-aged children with intellectual disability and normal intelligence
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ac13ae2b7de64dbb9dca02988a2316ca
work_keys_str_mv	AT jaunmoon comparativeefficacyoflevetiracetamforepilepsyinschoolagedchildrenwithintellectualdisabilityandnormalintelligence AT jiyoonhan comparativeefficacyoflevetiracetamforepilepsyinschoolagedchildrenwithintellectualdisabilityandnormalintelligence
_version_	1718412856157798400

Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence

Ejemplares similares